DBV Technologies S.A. (NASDAQ:DBVT) Sees Large Drop in Short Interest

DBV Technologies S.A. (NASDAQ:DBVT) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 95,200 shares, a decline of 40.5% from the April 30th total of 160,100 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily volume of 419,100 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. 71.74% of the stock is owned by institutional investors.

DBV Technologies Price Performance

Shares of NASDAQ DBVT traded down $0.51 during mid-day trading on Friday, hitting $8.30. The company had a trading volume of 47,266 shares, compared to its average volume of 191,486. The business’s 50-day simple moving average is $8.44 and its 200-day simple moving average is $5.50. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $12.78. The firm has a market cap of $227.34 million, a P/E ratio of -1.84 and a beta of -0.66.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The company had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. As a group, sell-side analysts predict that DBV Technologies will post -7.05 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on DBVT shares. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Friday, May 9th. The Goldman Sachs Group raised shares of DBV Technologies to a “sell” rating and set a $7.25 target price on the stock in a research note on Thursday. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Tuesday, May 27th. JMP Securities upped their price target on shares of DBV Technologies from $15.00 to $21.00 and gave the stock a “market outperform” rating in a research note on Tuesday, May 27th. Finally, HC Wainwright upped their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a “buy” rating in a report on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $14.75.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.